Sella, Tal
Kantor, Olga
Weiss, Anna
Partridge, Ann H.
Metzger, Otto
King, Tari A. http://orcid.org/0000-0003-3602-2351
Funding for this research was provided by:
Pinchas Borenstein Talpiot Medical Leadership Program
American Physicians Fellowship for Medicine in Israel
Article History
Received: 9 March 2022
Accepted: 30 May 2022
First Online: 25 June 2022
Declarations
:
: Anna Weiss: Institutional sponsored research agreement from Myriad Laboratories, Inc. Otto Metzger: Stock and other ownership interests: Invitae. Honoraria: Grupo Oncoclinicas, Merck. Consulting or advisory role: Grupo Oncoclinicas, Resilience Care, Alliance for Clinical Trials in Oncology. Speakers' Bureau: AstraZeneca. Research funding (to institution): Eisai, Abbvie, Susan G. Komen for the Cure, Roche/Genentech, Pfizer, Cascadian Therapeutics. Patents, royalties, other intellectual property (to institution): Sanofi. Travel, accommodations, expenses: Grupo Oncoclinicas. Tari A. King: Speakers Honoraria and compensated service on Scientific Advisory Board: Exact Sciences (formerly Genomic Health). Compensated service for a Global Advisory Board: Besins Healthcare. The authors Tal Sella, Olga Kantor, and Ann H. Partridge declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.